NetScientific is an active transatlantic life sciences, sustainability and technology investment and commercialisation group. Portfolio company, NASDAQ-listed PDS Biotechnology (PDSB), in which NSCI holds a 4.72% equity stake, provided an update on 7 June 2022 post the ASCO (American Society of Clinical Oncology) 2022 meeting, on data presented on two of its ongoing Phase 2 studies leveraging its cancer immunotherapy platform Versamune®. The key highlights related to the progress of lead candida ....
08 Jun 2022
WH Ireland: NetScientific (NSCI) - PDS Biotechnology reports Phase 2 ASCO 2022 highlights from the NCI-led triple combination study, and from VERSATILE 002 study, for advanced HPV-associated cancers
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WH Ireland: NetScientific (NSCI) - PDS Biotechnology reports Phase 2 ASCO 2022 highlights from the NCI-led triple combination study, and from VERSATILE 002 study, for advanced HPV-associated cancers
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
08 Jun 2022 -
Author:
Matthew Davis | Emma Ulker -
Pages:
5
NetScientific is an active transatlantic life sciences, sustainability and technology investment and commercialisation group. Portfolio company, NASDAQ-listed PDS Biotechnology (PDSB), in which NSCI holds a 4.72% equity stake, provided an update on 7 June 2022 post the ASCO (American Society of Clinical Oncology) 2022 meeting, on data presented on two of its ongoing Phase 2 studies leveraging its cancer immunotherapy platform Versamune®. The key highlights related to the progress of lead candida ....